Skip to main content

Advertisement

SpringerLink
Log in

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Secondary hyperparathyroidism (SHPT) remains a treatment dilemma in pediatric dialysis patients. Recent experience with paricalcitol (P), a vitamin D analogue, in adults with SHPT has shown equal efficacy and improved survival compared to traditional treatment with calcitriol (C). We present our experience with (C) compared to (P) treatment in our pediatric dialysis patients with SHPT. Twenty-one patients (mean age 11.5±5 years) with SHPT (intact parathyroid hormone (iPTH) averaging 1,228±496 pg/ml) were studied. Seventeen received (C) followed by (P); while an additional four were treated with either (C=1) or (P=3) alone. After 26±8 weeks, average percent (%) decrease in iPTH was similar with (C) and (P) (−60.4±34% versus −65.4±28%, respectively; p=0.6). In the (P) group, the effective dose in children was greater than in adult trials based on kilogram weight. Episodes of hypercalcemia between the treatment groups were not different. However, episodes of elevated calcium × phosphorus product (Ca×P)≥70 mg2/dl2 occurred more frequently in the (C) group (odds ratio=1.5; p=0.01). Paricalcitol appears to be safe and effective in pediatric patients. Data suggest that dosing should be gauged according to degree of SHPT. This should serve as impetus for future pharmacokinetic studies in pediatric dialysis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. National Kidney Foundation (2005) K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S1–S103

    Google Scholar 

  2. Salusky I (2005) Are new Vitamin D analogues in renal disease superior to calcitriol? Pediatr Nephrol 20:393–398

    Article  Google Scholar 

  3. Sanchez CP (2003) Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment. Pediatr Drugs 5:763–776

    Article  Google Scholar 

  4. Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG, Brill JE, Gilli G, Slatopolsky E, Coburn JW (1987) “High-dose” calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32:89–95

    Article  CAS  Google Scholar 

  5. Mathias R, Salusky I, Harman W, Paredes A, Emans J, Segre G, Goodman W (1993) Renal bone disease in pediatric and young adult patients on hemodialysis in a children’s hospital. J Am Soc Nephrol 3:1938–1946

    CAS  PubMed  Google Scholar 

  6. Slatopolsky E, Brown A, Dusso A (1999) Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73:S14–S19

    Article  CAS  Google Scholar 

  7. Llach F, Velasquez Forero F (2001) Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 38:S20–S33

    Article  CAS  Google Scholar 

  8. Greenbaum L, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB (2005) Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol 20:622–630

    Article  Google Scholar 

  9. Cano F, Delucchi A, Wolff E, Rodriguez E, Fuentes A (1995) Calcitriol oral pulse therapy in children with renal osteodystrophy. Pediatr Nephrol 9:606–608

    Article  CAS  Google Scholar 

  10. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ (1989) Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274–279

    Article  CAS  Google Scholar 

  11. Quarles LD, Yohay DA, Carroll BA, Spritzer CF, Minda SA, Bartholomay D, Lobaugh BA (1994) Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710–1721

    Article  CAS  Google Scholar 

  12. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GB, Salusky IR (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160–1166

    Article  CAS  Google Scholar 

  13. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J (1998) 19-nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427–1432

    CAS  PubMed  Google Scholar 

  14. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C (2001) A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56:315–323

    CAS  PubMed  Google Scholar 

  15. Melnick JZ, Kommala D, Mattingly S, Amdahl M, Greenbaum WL (2004) Paricalcitol and calcitriol in treating SHPT children: a comparison of 2 studies. St. Louis, MO, GPRD, Abbott Laboratories, Abbott Park, IL; Pediatrics Medical College of Wisconsin, Milwaukee, WI [Abstract]. J Am Soc Nephrol SU-PO939

  16. Llach F, Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38(5Suppl 5):S45–S50

    Article  CAS  Google Scholar 

  17. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32:S48–S54

    Article  CAS  Google Scholar 

  18. Sprague SM, Llach F, Amdahl M, Tacetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483–1490

    Article  CAS  Google Scholar 

  19. Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E (2002) Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283–1288

    Article  CAS  Google Scholar 

  20. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456

    Article  CAS  Google Scholar 

  21. Korkor AB (1987) Reduced binding of 1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316:1573–1577

    Article  CAS  Google Scholar 

  22. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436–1443

    Article  CAS  Google Scholar 

  23. Carling T, Rastad J, Szabo E, Westin G, Akerstrom G (2000) Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 85:2000–2003

    CAS  PubMed  Google Scholar 

  24. Martin KJ, Gonzalez E, Lindberg JS, Taccetta C, Amdahl M, Malhotra K, Llach F (2001) Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 38:S57–S63

    Article  CAS  Google Scholar 

  25. Kuizon D, Goodman W, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205–211

    Article  CAS  Google Scholar 

  26. Sanchez CP, He YZ (2005) Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism. J Am Soc Nephrol 16:929–938

    Article  CAS  Google Scholar 

  27. Paczyk-Tomaszewska M, Ziókowska H, Debinski A, Sieniawska M (2000) Vitamin D metabolite requirements in dialysed children receiving recombinant human growth hormone. Nephrol Dial Transplant 15:375–378

    Article  Google Scholar 

  28. US Government (2006) VISN 21 Criteria for non-formulary use of paricalcitol. US Department of Veterans Affairs, USA

  29. Dobrez D, Mathes A, Amdahl M, Marx S, Melnick J, Sprague S (2004) Paricalcitol-treated patients experience improved hospitalization outcomes compared to calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19:1174–1181

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by a grant from Florida’s Department of Health, Children’s Medical Services.

Author information

Authors and Affiliations

  1. Division of Pediatric Nephrology, Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    Wacharee Seeherunvong

  2. Division of Pediatric Nephrology, Department of Pediatrics, University of Miami/Holtz Children’s Hospital, 1611 NW 12th Avenue, Annex 5, Miami, FL, 33126, USA

    Obioma Nwobi, Carolyn L. Abitbol, Jayanthi Chandar, José Strauss & Gastón Zilleruelo

Authors
  1. Wacharee Seeherunvong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Obioma Nwobi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carolyn L. Abitbol
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jayanthi Chandar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. José Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gastón Zilleruelo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carolyn L. Abitbol.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seeherunvong, W., Nwobi, O., Abitbol, C.L. et al. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 21, 1434–1439 (2006). https://doi.org/10.1007/s00467-006-0204-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-006-0204-5

Keywords

Search

Navigation